Latest News

Heading 1

with a request body that specifies how to map the columns of your import file to the associated CRM properties in HubSpot.... In the request JSON, define the import file details, including mapping the spreadsheet's columns to HubSpot data. Your request JSON should include the following fields:... entry for each column.

Heading 1

with a request body that specifies how to map the columns of your import file to the associated CRM properties in HubSpot.... In the request JSON, define the import file details, including mapping the spreadsheet's columns to HubSpot data. Your request JSON should include the following fields:... entry for each column.

News

Graphic announcing “A Letter to the PWS Community from Neurocrine Biosciences,” featuring a preview of the Neurocrine letter and FPWR and Neurocrine logos.
Neurocrine Biosciences Shares Letter with the PWS Community
Neurocrine Biosciences has shared a letter with the Prader-Willi syndrome (PWS) community. Earlier this year, Neurocrine Biosciences acquired Soleno Therapeutics and became the new steward of VYKAT® XR (diazoxide choline) extended-release tablets. Kyle Gano, CEO of Neurocrine, has shared a
PWS Medical Care at Every Age graphic featuring 2026 FPWR Conference speakers Dr. Sani Roy for ages 0–2, Dr. Amy Fleischman for ages 3–9, and Dr. Diane Stafford for teens and adults.
PWS Medical Care at Every Age | 2026 FPWR Conference
Medical needs change as people with Prader-Willi syndrome grow, and families often have questions about what to watch for, which specialists to see, and what care should look like at each stage. At this year’s FPWR Family Conference, three experienced
Balancing Benefit, Risk, and Access to VYKAT XR
As the PWS community gains more real-world experience with VYKAT XR, important conversations are taking place about how to balance the medication’s potential benefits with known risks. FPWR believes both deserve careful consideration. Recent reports of 7 deaths and more
New Study Opportunity for Prader-Willi Syndrome: Now Enrolling RM-718
A new clinical study is now enrolling individuals with Prader-Willi syndrome (PWS), offering families the opportunity to explore a potential new treatment for obesity and hyperphagia. RM-718 is an investigational medication taken as a once-weekly injection and is currently being

Subscribe to hope.

If you're looking for the latest information on Prader-Willi syndrome, you’ve come to the right place. FPWR Updates is your source for up-to-date information.

Heading 1

with a request body that specifies how to map the columns of your import file to the associated CRM properties in HubSpot.... In the request JSON, define the import file details, including mapping the spreadsheet's columns to HubSpot data. Your request JSON should include the following fields:... entry for each column.

Evan and Dr. Fallah